Originally published by our sister publication Clinical Oncology News
The FDA approved Hepzato Kit (melphalan for Injection/Hepatic Delivery System) containing melphalan (Hepzato, Delcath Systems Inc.) as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues or lung that is amenable to resection or